A unicorn startup or unicorn company is a private company with a valuation over $1 billion USD. Unicorns are ‘startups’, i.e they do not include post-exit, acquired or listed companies, nor do they include ‘mature’ incumbents.
As of 30 May 2022, there are 93 HealthTech Unicorns around the world who are now collectively valued at $228B.
BenevolentAI left the list in Apr 2022 via SPAC.
EQRx left the list in Dec 2021 via IPO.
Pear Therapeutics was acquired by Thimble Point (SPAC) in Dec 2021.
VillageMD was acquired by Walgreens Boots Alliance in Oct 2021.
Ginkgo BioWorks left the list in Sep 2021 via IPO.
Maven Clinic joined the list in Aug 2021.
Grail was acquired by Illumina in Aug 2021.
Roivant Sciences left the list in May 2021 via IPO.
Outcome Health was acquired by PatientPoint in Mar 2021.
Aledade, EQRx, Innovaccer, ATAI Life Sciences, Brii BioSciences, Evidation Health, Ginger, Komodo Health, Radiology Partners, Rightway, Unite Us, DispatchHealth, Pear Therapeutics, Insitro and Shulan Health joined the list in Jan – Mar 2021.
Recursion Pharmaceuticals left the list in Apr 2021 via IPO.
Oscar Health left the list in Mar 2021 via IPO.
Sema4 was acquired by Casdin Capital and Corvex Management (SPAC) in Feb 2021.
23andMe was acquired by Virgin Galactic Acquisition Corporation (SPAC) in Feb 2021.
Clover Health left the list in Jan 2021 via IPO.
|Company||Country||Last Round Date||Last Round Type||Valuation|
|Devoted Health||United States||Oct 2021||$1.15B Series D||$12.7B|
|Biosplice Therapeutics (formerly Samumed)||United States||Apr 2021||$120M VC Round||$12.4B|
|Tempus||United States||Dec 2020||$200 M Series G-2||$8B|
|Caris Life Sciences||United States||May 2021||$830M PE Round||$7.83B|
|WeDoctor (GuaHao)||China||Feb 2021||$411M Series F||$7B|
|Doctolib||France||Mar 2022||$549M Series F||$6.4B|
|Hinge Health||United States||Oct 2021||$600M Series E||$6.2B|
|Lyra Health||United States||Jan 2022||$235M Series F||$5.85B|
|Cityblock Health||United States||Sep 2021||$400M Series D||$5.7B|
|United Imaging Healthcare||China||Sep 2017||$500M Series A||$5.1B|
|Ro||United States||Mar 2021||$500M Series D||$5B|
|Reify Health||United States||Apr 2022||$220M Series D||$4.8B|
|Cerebral||United States||Dec 2021||$300M Series C||$4.8B|
|Color||United States||Nov 2021||$100M Series E||$4.6B|
|Olive||United States||Jun 2021||$400M Series H||$4B|
|Radiology Partners||United States||Mar 2021||$12.6M Venture Round||$4B|
|Medlinker||China||Dec 2021||$514 Milion Series E||$3.9B|
|Intarcia Therapeutics||United States||Aug 2019||Undisclosed||$3.8B|
|Abogen||China||Nov 2021||$300M Series C||$3.7B|
|Noom||United States||May 2021||$540M Series F||$3.7B|
|Ottobock||Germany||Dec 2019||$106.9M Debt||$3.5B|
|PharmEasy||India||Nov 2021||Private Equity||$3.4B|
|Komodo Health||United States||Mar 2021||$220M Series E||$3.3B|
|Innovaccer||United States||Dec 2021||$150 Million Series E||$3.1B|
|Carbon Health||United States||Jul 2021||$350M Series D||$3B|
|CMR Surgical||United Kingdom||Jun 2021||$600M Series D||$3B|
|Oura||Finland||Apr 2022||VC Round||$2.55B|
|Somatus||United States||Feb 2022||$325M Series E||$2.5B|
|Insitro||United States||Mar 2021||$400M Series C||$2.4B|
|SWORD Health||United States||Nov 2021||$163M Series D||$2B|
|Spring Health||United States||Sep 2021||$190M Series C||$2B|
|KRY||Sweden||Apr 2021||$319M Series D||$2B|
|Virta Health||United States||Apr 2021||$133M Series D||$1.9B|
|Keep||China||Jan 2021||$360M Series F||$1.9B|
|Aledade||United States||Jan 2021||$100M Series D||$1.9B|
|Calm||United States||Dec 2020||$75M Series C||$1.9B|
|Zocdoc||United States||Aug 2015||$130M Series D||$1.8B|
|Saliogen Therapeutics||United States||Jan 2022||$115M Series B||$1.7B|
|DispatchHealth||United States||Mar 2021||$200M Series D||$1.7B|
|Unite Us||United States||Mar 2021||$150M Series C||$1.7B|
|Truepill||United States||Oct 2021||$142M Series D||$1.6B|
|Verily||United States||Dec 2020||$700M VC Round||$1.6B|
|Athelas||United States||Jan 2022||$132M VC Round||$1.5B|
|Curefit||United States||Nov 2021||$145M Series F||$1.5B|
|Collective Health||United States||May 2021||$280M Series F||$1.5B|
|K Health||United States||Jan 2021||$132M Series E||$1.5B|
|Strava||United States||Nov 2020||$110M Series F||$1.5B|
|HeartFlow||United States||Jun 2019||$65M Series E||$1.5B|
|Valgen Medtech||China||May 2021||$188M Series B||$1.43B|
|Clarify Health||United States||Apr 2022||$150M Series D||$1.4B|
|Pristyn Care||India||Dec 2021||$96M Series E||$1.4B|
|Papa||United States||Nov 2021||$150M Series D||$1.4B|
|Yaoshibang||China||Jul 2021||$270M Series E||$1.35B|
|Athletic Greens||United States||Jan 2022||$115M VC Round||$1.32B|
|Alzheon||United States||Apr 2022||$50M Series D||$1.31B|
|Shulan Health||China||Mar 2021||Series D||$1.24B|
|Elemy||United States||Oct 2021||$219M Series B||$1.2B|
|Prime Medicine||United States||July 2021||$200M Series B||$1.2B|
|Insightec||Israel||Apr 2021||$136M Venture – Series Unknown||$1.2B|
|Modern Health||United States||Feb 2021||$74M Series D||$1.2B|
|IntelyCare||United States||Apr 2022||$115M Series C||$1.1B|
|Ginger||United States||Mar 2021||$100M Series E||$1.1B|
|Rightway||United States||Mar 2021||$100M Series C||$1.1B|
|Biofourmis||Singapore||Apr 2022||$300M Series D||$1B|
|BostonGene||United States||Apr 2022||$150M Series B||$1B|
|NexHealth||United States||Apr 2022||$125M Series C||$1B|
|Omada Health||United States||Feb 2022||$192M Series E||$1B|
|Mindmaze||Switzerland||Feb 2022||$105M Venture Series Unknown||$1B|
|Modernizing Medicine||Switzerland||Feb 2022||$53.4M Venture Series Unknown||$1B|
|Transcarent||United States||Jan 2022||$200M Series C||$1B|
|Alto Pharmacy||United States||Jan 2022||$200M Series E||$1B|
|Cadence Solutions||United States||Dec 2021||$100M Series B||$1B|
|Dental Monitoring||France||Oct 2021||$150M PE Round||$1B|
|TrialSpark||United States||Sep 2021||$156M Series C||$1B|
|Mammoth Biosciences||United States||Sep 2021||$150M Series D||$1B|
|Miaoshou Doctor||China||Aug 2021||$232M Series F||$1B|
|Maven Clinic||United States||Aug 2021||$110M Series D||$1B|
|dMed Biopharmaceutical||China||Jul 2021||$50M Series C||$1B|
|SonderMind||United States||Jul 2021||$150M Series C||$1B|
|LetsGetChecked||Ireland||Jun 2021||$150M Series D||$1B|
|Thirty Madison||United States||Jun 2021||$140M Series C||$1B|
|Capsule||United States||Apr 2021||$300M Series D||$1B|
|Fiture||China||Apr 2021||$300M Series B||$1B|
|Evidation Health||United States||Mar 2021||$153M Series E||$1B|
|Zwift||United States||Sep 2020||$450M Series C||$1B|
|Orca Bio||United States||Jun 2020||$192M Series D||$1B|
|Gympass||United States||Jun 2019||$300M Series D||$1B|
|Aprogen||South Korea||May 2019||–||$1B|
|LinkDoc||China||Jul 2018||$151M Series D||$1B|
|iCarbonX||China||Jun 2018||$141.77M Series A||$1B|
|DXY||China||Apr 2018||$100M Series D||$1B|
|OrCam||Israel||Feb 2018||$30.4M VC Round||$1B|
|PointClickCare||Canada||Feb 2018||$146M Series D||$1B|
$11.4B of EdTech Venture Funding for 1H 2022.A moderate slow-down would deliver around $17B+ for the full year.
Climate Tech set a record half with $26.8B in venture funding in 968+ deals. Q2 has slowed quite significantly, we expect $40B+ for the full year.
Funding continues to flow in the first half of 2022 with $49.7B growth capital for health firms, despite a correction for digital and concerns around falling valuations.